Escudero X, Guarner J, Galindo-Fraga A, Escudero-Salamanca M, Alcocer-Gamba MA, Del-Río C

Language: Spanish
References: 23
Page: 170-177
PDF size: 297.02 Kb.

ABSTRACT

The Coronavirus pandemic (COVID-19) is one of the most devastating in this century. It originated in China in December 2019 caused by the SARS-CoV-2 virus, and in less than a month it had been classified as an «International Public Health Emergency». To date there are nearly 3 million people infected and more than 250,000 deaths caused by the disease worldwide. Initially it affects the respiratory tract with atypical pneumonia and in severe cases it produces systemic inflammation with cytokine storm that can cause rapid deterioration with circulatory and respiratory failure, coagulopathy and a lethality rate of approximately 7%. In Mexico, the first case was detected in February 2020, and to date there are 26,616 confirmed cases and 2,961 deaths throughout the country. The low number of diagnostic tests conducted in our country clearly underestimates the real incidence and impact of the disease. The most affected groups are those with risk factors such as age over 60, presence of hypertension, diabetes or cardiovascular disease. Of the confirmed cases, 15% are healthcare workers. There is no specific treatment or vaccine yet, so it is important to have hygiene, social isolation and personal protection measures. Health, social and economic consequences could have great impact in the near future.

REFERENCES

1. Stern AM, Markel H. International efforts to control infectious diseases. J Am Med Assoc. 2004; 292: 1474-1479.

2. Frank TD, Carter A, Jahagirdar D, Biehl MH, Douwes-Schultz D, Larson SL et al. Global, regional and national incidence, prevalence and mortality of HIV 1980-2017 and forecast to 2030 for 195 countries and territories: A systematic analysis for the burden of disease, injuries and risk factors study 2017. J Am Med Assoc. 2019; 6: e831-e859.

3. Del Río C, Mehta AK, Lyon GM 3rd, Guarner J. Ebola hemorrhagic fever in 2014: a tale of an evolv-ing epidemic. Ann Intern Med. 2014; 161: 746-748.

4. Lowe R, Barcellos C, Brasil P, Cruz OG, Álvez Honorio N, Kuper H et al. The Zika virus epidemic in Brazil: From discovery to future implications. Int J Environ Res Public Health. 2018; 15: 1-18.

5. World Health Organization. The fifth meeting of the Emergency Committee under the International Health Regulations (2005) regarding microcephaly other neurological disorders and Zika virus. November 18, 2016. http://www.who.int

6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497-506.

7. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG et al. A new coronavirus associated with hu-man respiratory disease in China. Nature. 2020; 579: 265-269.

8. Del Río C, Melani PN. COVID-19 New insights of a rapidly changing epidemic. J Am Med Assoc. 2020; 323: 1339-1340.

9. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2 [published online ahead of print, 2020 Apr 7]. Emerg Infect Dis. 2020; 26 (7): doi: 10.3201/eid2607.200282.

10. Zou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with adult COVID-19 in Wuhan, China: a retrospective cohort study. J Am Med Assoc. 2020; 395: 1054-1062.

11. Guan WJ, Ni ZY, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382 (18): 1708-1720.

12. Ministerio de Salud de España. Enfermedad por coronavirus (COVID-19). Actualización 26 de marzo de 2020 (Versión 2). [Accesado 10 de abril de 2020] Disponible en: https://mscbs.es/ccays/alertasActual/nCov-China

13. European Centre of Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK, 8th Update. [Accesado 10 de abril de 2020] Available in: https://ecdc.europa.eu.

14. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention [published online ahead of print, 2020 Feb 24]. JAMA. 2020. doi: 10.1001/jama.2020.2648.

15. World Health Organization. Coronavirus disease (COVID-19) pandemic. [Accesado 14 de abril de 2020] Available in: https://www.who.int/emergencies/diseases/novel-coronavirus-2019

16. Babiker A, Myers CW, Hill CE, Guarner J. SARS-CoV-2 testing. Am J Clin Pathol. 2020; 153 (6): 706-708. doi: 10.1093/ajcp/aqaa052.

17. World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases. Interim guidance 2 March 2020. [Accesado el 12 de abril de 2020] Available in: https://apps.who.int/iris/handle/10665/331329

18. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581 (7809): 465-469. doi: 10.1038/s41586-020-2196-x.

19. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment. J Am Coll Cardiol. 2020; 75 (20): 2623-2624. doi: 10.1016/j.jacc.2020.04.016.

20. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G et al. A trial of lipinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020. doi: 10.1056/NEJMoa2001282.

21. Omer SB, Malani P, Del Rio C. The COVID-19 pandemic in the US: a clinical update [published online ahead of print, 2020 Apr 6]. JAMA. 2020. doi: 10.1001/jama.2020.5788.

22. Secretaría de Salud de México. Dirección General de Epidemiología. Comunicado Técnico diario. [Accesado el 14 de abril del 2020] Disponible en: http://www.gob.mx/salud/documentos/coronavirus-covid-19

23. Laurence Boone. OECD Interim Outlook. Coronavirus: The world economy at risk. March 02, 2020. Available in: http://www.oecd.org/economy/outlook